Taysha Gene Therapies (TSHA) Consolidated Net Income (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Consolidated Net Income data on file, last reported at -$98.1 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 243.13% year-over-year to -$98.1 million; the trailing twelve-month figure through Mar 2026 stood at -$236.7 million (down 88.95% YoY), and the FY2025 full-year result was -$183.0 million, up 7.9% from the prior year.
• Consolidated Net Income fell to -$98.1 million in Q1 2026, from -$25.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$14.4 million in Q4 2024 to a low of -$98.1 million in Q1 2026.
• A 5-year average of -$40.7 million and a median of -$34.1 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income soared 72.12% in 2023 and plunged 243.13% in 2026, its largest moves.
• Tracing TSHA's Consolidated Net Income over 5 years: stood at -$56.0 million in 2022, then soared by 72.12% to -$15.6 million in 2023, then rose by 8.06% to -$14.4 million in 2024, then sank by 77.25% to -$25.4 million in 2025, then slumped by 285.64% to -$98.1 million in 2026.
• Business Quant data shows TSHA's Consolidated Net Income at -$98.1 million in Q1 2026, -$25.4 million in Q4 2025, and -$62.0 million in Q3 2025.